\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ discontinuous\\ nodular\\ enhancement\\ on\\ contrast\\ enhanced\\ ct\\ with\\ positive\\ nm\\ rbc\\ scan\\.\ \(0\)\
\-\ hepatic\\ hemangioma\ \(3\)\
\-\ hemangioma\ \(165\)\
\-\ \\(hepatocellular\\ carinoma\\,fnh\\,hepatic\\ adenoma\\,hypervascular\\ metastases\\ would\\ not\\ be\\ expected\\ to\\ have\\ positive\\ rbc\\ scan\\,\\ although\\ could\\ potentially\\ have\\ similar\\ appearance\\ on\\ ct\\)\ \(0\)\
\-\ abnormal\\ hepatic\\ finding\\ on\\ ct\\ scan\\ in\\ patient\\ with\\ abdominal\\ pain\\.\ \(0\)\
\-\ a\\ hemangioma\\ is\\ defined\\ pathologically\\ as\\ a\\ tumor\\ composed\\ of\\ multiple\\ vascular\\ channels\\ lined\\ by\\ a\\ single\\ layer\\ of\\ endothelial\\ cells\\ supported\\ by\\ a\\ thin\\,\\ fibrous\\ stroma\\.\\ \\ they\\ are\\ divided\\ into\\ two\\ catagories\\;\\ typical\\ and\\ giant\\.\\ \\ typical\\ hemangiomas\\ are\\ small\\,\\ asymptomatic\\ and\\ discovered\\ incidentally\\.\\ \\ giant\\ hemangiomas\\ are\\ \\>5\\ cm\\ and\\ may\\ hemorrhage\\ or\\ thrombose\\.\ \(0\)\
\-\ ct\\ findings\\ include\\ a\\ hypodense\\,\\ well\\ circumscribed\\ lesion\\ on\\ pre\\-contrast\\ ct\\ with\\ nodular\\ intense\\ peripheral\\ enhancement\\ on\\ dynamic\\ bolus\\ contrast\\ phase\\.\\ \\ nuclear\\ spect\\ imaging\\ \\ shows\\ increased\\ activity\\ of\\ 99\\-tc\\ labled\\ rbc\\'s\\ on\\ delayed\\ blood\\ pool\\ imaging\\;\\ however\\,\\ this\\ study\\ is\\ only\\ useful\\ if\\ the\\ tumor\\ in\\ question\\ is\\ 2\\-3\\ cm\\ or\\ greater\\ in\\ size\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ rbc\\:\\ 0\\.08160825622965533\ \(0\)\
\-\ hemangioma\\:\\ 0\\.06328684226854779\ \(0\)\
\-\ hepatic\\:\\ 0\\.05914631522330407\ \(0\)\
\-\ hemangiomas\\:\\ 0\\.05877360069060793\ \(0\)\
\-\ catagories\\:\\ 0\\.04870452167937292\ \(0\)\
\-\ thrombose\\:\\ 0\\.04870452167937292\ \(0\)\
\-\ 99\\-tc\\:\\ 0\\.04870452167937292\ \(0\)\
\-\ labled\\:\\ 0\\.04870452167937292\ \(0\)\
\-\ giant\\:\\ 0\\.0454700337919788\ \(0\)\
\-\ carinoma\\:\\ 0\\.04263484052651043\ \(0\)\
\-\ scan\\:\\ 0\\.03965090818397202\ \(0\)\
\-\ nodular\\:\\ 0\\.039606738200131615\ \(0\)\
\-\ discontinuous\\:\\ 0\\.03795363687796235\ \(0\)\
\-\ typical\\:\\ 0\\.03786128943812152\ \(0\)\
\-\ channels\\:\\ 0\\.036565159373647946\ \(0\)\
\-\ nm\\:\\ 0\\.03598305707719587\ \(0\)\
\-\ bolus\\:\\ 0\\.03598305707719587\ \(0\)\
\-\ fnh\\:\\ 0\\.034975755658444733\ \(0\)\
\-\ endothelial\\:\\ 0\\.034975755658444733\ \(0\)\
\-\ pre\\-contrast\\:\\ 0\\.03453353075417105\ \(0\)\
\-\ lined\\:\\ 0\\.03374291835836623\ \(0\)\
\-\ ct\\:\\ 0\\.03301943793900671\ \(0\)\
\-\ stroma\\:\\ 0\\.03188395572509986\ \(0\)\
\-\ supported\\:\\ 0\\.0316269390641336\ \(0\)\
\-\ pathologically\\:\\ 0\\.03138134921567596\ \(0\)\
\-\ spect\\:\\ 0\\.03138134921567596\ \(0\)\
\-\ positive\\:\\ 0\\.030639619782144936\ \(0\)\
\-\ dynamic\\:\\ 0\\.030495478220785462\ \(0\)\
\-\ layer\\:\\ 0\\.029913375924333383\ \(0\)\
\-\ divided\\:\\ 0\\.029732216682217413\ \(0\)\
\-\ composed\\:\\ 0\\.028906074505582253\ \(0\)\
\-\ hypervascular\\:\\ 0\\.027924410542944395\ \(0\)\
\-\ potentially\\:\\ 0\\.02767323720550375\ \(0\)\
\-\ pool\\:\\ 0\\.02767323720550375\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.027202752076551776\ \(0\)\
\-\ question\\:\\ 0\\.027091134909051667\ \(0\)\
\-\ 2\\-3\\:\\ 0\\.02547417571588692\ \(0\)\
\-\ cm\\:\\ 0\\.02532548196482857\ \(0\)\
\-\ enhancement\\:\\ 0\\.025309268133956196\ \(0\)\
\-\ hypodense\\:\\ 0\\.025153804126658467\ \(0\)\
\-\ intense\\:\\ 0\\.025000325871923246\ \(0\)\
\-\ useful\\:\\ 0\\.024634307167275726\ \(0\)\
\-\ nuclear\\:\\ 0\\.024358006501117375\ \(0\)\
\-\ on\\:\\ 0\\.023996387150235183\ \(0\)\
\-\ discovered\\:\\ 0\\.02326159247501882\ \(0\)\
\-\ expected\\:\\ 0\\.022992033556955664\ \(0\)\
\-\ \\;\\:\\ 0\\.022380344623785565\ \(0\)\
\-\ phase\\:\\ 0\\.02220844131695998\ \(0\)\
\-\ imaging\\:\\ 0\\.02212236270116688\ \(0\)\
\-\ tumor\\:\\ 0\\.022013616592384655\ \(0\)\
\-\ incidentally\\:\\ 0\\.021402629841752452\ \(0\)\
\-\ contrast\\:\\ 0\\.02113564294815365\ \(0\)\
\-\ circumscribed\\:\\ 0\\.020984743575423057\ \(0\)\
\-\ have\\:\\ 0\\.020446829595194383\ \(0\)\
\-\ enhanced\\:\\ 0\\.02020145372791143\ \(0\)\
\-\ metastases\\:\\ 0\\.020169792541673944\ \(0\)\
\-\ defined\\:\\ 0\\.019892721913577417\ \(0\)\
\-\ adenoma\\:\\ 0\\.019715438407768023\ \(0\)\
\-\ thin\\:\\ 0\\.019404494563024434\ \(0\)\
\-\ are\\:\\ 0\\.01930730175463428\ \(0\)\
\-\ delayed\\:\\ 0\\.019215361018039667\ \(0\)\
\-\ single\\:\\ 0\\.01913624469884216\ \(0\)\
\-\ fibrous\\:\\ 0\\.019084122973795983\ \(0\)\
\-\ cells\\:\\ 0\\.01893064471906076\ \(0\)\
\-\ similar\\:\\ 0\\.018517605629507668\ \(0\)\
\-\ greater\\:\\ 0\\.01773323954514089\ \(0\)\
\-\ activity\\:\\ 0\\.017712964799898003\ \(0\)\
\-\ could\\:\\ 0\\.01741744720348371\ \(0\)\
\-\ n\\/a\\:\\ 0\\.017100589211928655\ \(0\)\
\-\ peripheral\\:\\ 0\\.01708250454151446\ \(0\)\
\-\ they\\:\\ 0\\.017010752080040364\ \(0\)\
\-\ would\\:\\ 0\\.01680092198023254\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.01595907402207783\ \(0\)\
\-\ although\\:\\ 0\\.01594436066616908\ \(0\)\
\-\ size\\:\\ 0\\.015828043488280503\ \(0\)\
\-\ by\\:\\ 0\\.015722330422595302\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.015714124774453234\ \(0\)\
\-\ \\>\\:\\ 0\\.01568600836833461\ \(0\)\
\-\ study\\:\\ 0\\.015533874899778779\ \(0\)\
\-\ vascular\\:\\ 0\\.015479576065876776\ \(0\)\
\-\ finding\\:\\ 0\\.015215809420102106\ \(0\)\
\-\ only\\:\\ 0\\.014195644522016219\ \(0\)\
\-\ 5\\:\\ 0\\.013813041007978803\ \(0\)\
\-\ two\\:\\ 0\\.013521167058651964\ \(0\)\
\-\ appearance\\:\\ 0\\.013502246280301887\ \(0\)\
\-\ abnormal\\:\\ 0\\.013464598012789564\ \(0\)\
\-\ include\\:\\ 0\\.013243941922819262\ \(0\)\
\-\ however\\:\\ 0\\.013145679865177184\ \(0\)\
\-\ shows\\:\\ 0\\.012979965191872257\ \(0\)\
\-\ blood\\:\\ 0\\.012886249019388394\ \(0\)\
\-\ if\\:\\ 0\\.01281073720320793\ \(0\)\
\-\ \\,\\:\\ 0\\.011965085768719883\ \(0\)\
\-\ abdominal\\:\\ 0\\.011800658774155332\ \(0\)\
\-\ increased\\:\\ 0\\.011549639678451136\ \(0\)\
\-\ into\\:\\ 0\\.01123384733679396\ \(0\)\
\-\ or\\:\\ 0\\.01106654971230616\ \(0\)\
\-\ a\\:\\ 0\\.010955795630348101\ \(0\)\
\-\ small\\:\\ 0\\.010876106543542092\ \(0\)\
\-\ well\\:\\ 0\\.01068000526502017\ \(0\)\
\-\ \\'s\\:\\ 0\\.010409097339044448\ \(0\)\
\-\ may\\:\\ 0\\.010355405353028308\ \(0\)\
\-\ findings\\:\\ 0\\.010048822849668284\ \(0\)\
\-\ multiple\\:\\ 0\\.009943679577233529\ \(0\)\
\-\ lesion\\:\\ 0\\.009616327215472125\ \(0\)\
\-\ is\\:\\ 0\\.009319736658310368\ \(0\)\
\-\ be\\:\\ 0\\.007280423885878061\ \(0\)\
\-\ as\\:\\ 0\\.007141312187260374\ \(0\)\
\-\ in\\:\\ 0\\.006984484477462789\ \(0\)\
\-\ not\\:\\ 0\\.006822202606309035\ \(0\)\
\-\ pain\\:\\ 0\\.005765790980832788\ \(0\)\
\-\ this\\:\\ 0\\.00531015034980184\ \(0\)\
\-\ patient\\:\\ 0\\.004732552104510431\ \(0\)\
\-\ \\(\\:\\ 0\\.0039909487637782345\ \(0\)\
\-\ \\)\\:\\ 0\\.003942197193996161\ \(0\)\
\-\ and\\:\\ 0\\.0029835746806445044\ \(0\)\
\-\ to\\:\\ 0\\.002359492311839703\ \(0\)\
\-\ with\\:\\ 0\\.0019392957362965148\ \(0\)\
\-\ of\\:\\ 0\\.0019310022231710789\ \(0\)\
\-\ \\.\\:\\ 0\\.001569040269495968\ \(0\)\
\-\ the\\:\\ 0\\.000763808202782463\ \(0\)\
